Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Kangstem Biotech Co. Ltd. (217730:KRX), powered by AI.
Kangstem Biotech Co. Ltd. is currently trading at ₩2,700. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Kangstem Biotech Co. Ltd. on Alpha Lenz.
Kangstem Biotech Co. Ltd.'s P/E ratio is -24.2.
“Kangstem Biotech Co. Ltd. trades at a P/E of -24.2 (undervalued) with modest ROE of -18.7%.”
Ask for details →Kangstem Biotech Co. Ltd. is a biotechnology company that focuses primarily on the development and commercialization of stem cell therapies. The company's primary purpose is to leverage advanced stem cell technologies for innovative medical solutions, transforming regenerative medicine and offering new treatment options for various conditions. With a strong emphasis on research and development, Kangstem Biotech is instrumental in exploring the potential of stem cells in treating autoimmune diseases, skin conditions, and neurodegenerative disorders. Operating in the cutting-edge sector of biotechnology, Kangstem Biotech impacts both the healthcare and pharmaceutical industries by striving to introduce pioneering therapies that could significantly enhance patient outcomes. The company's role in the financial market is linked to its efforts in pushing the boundaries of medical science, attracting investors interested in the burgeoning field of biotech innovation. As a key player in a rapidly evolving industry, Kangstem Biotech contributes to scientific advancements and economic growth through its ongoing commitment to developing effective and sustainable medical treatments.
“Kangstem Biotech Co. Ltd. trades at a P/E of -24.2 (undervalued) with modest ROE of -18.7%.”
Ask for details →Kangstem Biotech Co. Ltd. (ticker: 217730) is a company listed on KRX in the Healthcare sector (Biotechnology). It has approximately 97 employees. Market cap is $253.9B.
The current price is ₩2,700 with a P/E ratio of -24.23x and P/B of 3.7x.
ROE is -18.75% and operating margin is -494.56%. Annual revenue is $3.6B.